Медико-биологический
информационный портал
для специалистов
 
БИОМЕДИЦИНСКИЙ ЖУРНАЛ Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"
(ФГБУН ИТ ФМБА России)

Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 11, Art. 31 (pp. 376-389)    |    2010       

№ гос. регистрации: 0421000002031
»

Effectiveness correction of anemia induced imatinib therapy in chronic myeloid leukemia patients
Romanenko N.A., Abdulkadyrov K.M., Bessmeltsev S.S.

"Russian Research Institute of Hematology and Transfusiology", Russian Federal Medico-biological Agency, St.-Petersburg



Brief summary

The article presents the results efficiency application of preparations of recombinant human erythropoietin (EPO) to correct anemia in patients with chronic myeloid leukemia (CML). There were studied 90 patients with CML received Imatinib as the main treatment for 6-48 months. The anemia was revealed in 36 patients (40%), the degrees of anemia (by WHO classification) were variety: I degree was at 29 patients, II degree - at 5, III degree - at 1 and IV degree - at 1 patient. The sixteen patients received EPO preparations only to correct the anemia, and two patients (III-d and IV-th degrees) received red blood transfusions before EPO therapy. The period of EPO-therapy was mean 9.7+4.6 weeks. The effectiveness of treatment was evaluated as hemoglobin (Hb) concentration achieving to 120 g/l or increasing above 20 g/l. The positive response was achieved at 13 (72.2%) out of 18 patients who received EPO preparations. The level of Hb concentration increased from 92.4+10.8 g/l to 124.1+20.8 g/l in the average. However the most patients decreased the hemoglobin level to the initial Hb concentration after abolition of EPO during 1-2 months. It was caused the toxicity effect of Imatinib on to erythropoiesis. Therefore these patients were continued (with period of break off) treatment of EPO preparations (for 16-18 months) till the Hb level increased up to 120 g/l. This approach to cure made sure taking the basic preparation Imatinib with non-stop. There was no progression of the main disease for the observation period in CML patients who received EPO preparations.


Key words

chronic myeloid leukemia, recombinant erythropoietin, anemia, tyrosine kinases inhibitor, Imatinib, erythropoiesis, hemoglobin





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list




Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100